Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01121536 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT01121536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01121536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Lead sponsor
Cephalon
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2010
Completion date
October 31, 2013
Enrollment
867 (actual)
Sites
158

Conditions

As the registry lists them; a condition with its own page is linked.

depression